system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, METHODS, METHODS, METHODS, RESULTS. Meshes: Adenine, Dinucleotide Repeats, Female, Genetic Predisposition to Disease, Genotype, Humans, Leiomyoma, Polymerase Chain Reaction, Polymorphism, Genetic, Receptors, Estrogen, Thymine, Uterine Neoplasms.
user
Is estrogen receptor thymine-adenine dinucleotide repeat polymorphism associated with susceptibility to leiomyoma? Context: To evaluate the association between leiomyomas and estrogen receptor gene polymorphism. Prospective study. Department of gynecology and genetics. Women with (n = 159) or without leiomyomas (n = 131). Polymerase chain reaction was used to detect dinucleotide (thymine-adenine [TA]) repeat polymorphisms upstream of the estrogen receptor gene. Genotypes were classified as A through P according to the number of the TA repeats from 12 to 27. Distributions of TA repeat for estrogen receptor in both groups were compared. Genotypes A to E were detected in 10.7%, 18.9%, 15.7%, 16.4%, and 4.4%, respectively, of women with leiomyomas and 4.2%, 9.5%, 20.6%, 19.1%, and 10.3% of women without leiomyomas. Women with genotypes A and B (12 or 13 TA repeats) have a higher risk for leiomyomas, and those with genotype E (16 TA repeats) have a lower risk.
assistant
Estrogen receptor gene polymorphism probably contributes to the pathogenesis of leiomyoma and may predict the susceptibility to leiomyoma. The 12 and 13 TA repeats are associated with a higher risk of leiomyoma. Final Decision: yes